Fabiotics Co., Ltd., founded in 2024, is a leading China- based biotechnology company dedicated to delivering microbial solutions for human health in an evolving environment. The company has been awarded the titles of “Innovative Startup” and “Science & Technology Startup” in China, selected for the “Hundred Talents Program” of Fujian Province, and received a Merit Award at the 2025 China Entrepreneurship and Innovation Competition......Its flagship strains include DePlastox™ PD01, the world’s first human-derived strain with clinical evidence for microplastic excretion and detoxification.
What We Offer
World-Class Microbiology Platform
-High-throughput screening, mutation and identification
-Strict anaerobic culture platform
-In vitro bionic/animal test platform
Proprietary Bioprocess Innovation & Development
-Strictly Anaerobic Production Technology
-Innovative concentration and drying technology
-Industry-leading stability of probiotic powders
Premium Ingredient and Formulation Solution
-High Density Active Probiotics
-Formulation & Application Development
-Postbiotic and Synbiotic Solution
DePlastox™ PD01
The World's First Clinically Evidenced Strain For "Plastic Excretion and Detoxification"
Core Data 1: Superior Plastic Excretion Power
-Promoting the Excretion of Different Types of Commonly Ingested Microplastic in Human
-91.35% Reduction of PS Residue In the murine model of human dietary microplastic exposure
Core Data 2: Beyond Excretion — Detoxification Is The Key
-Suppressing Gut Oxidative Stress Following Microplastic Invasion: CAT,GPX,SOD and Nox
-Selectively Reducing Microplastic-Induced Intestinal Inflammatory Factors
-Selectively Inhibiting Microplastic-Induced Obesity Symptoms
Core Data 3: Robust Barrier & Gut Health Restoration
-Enhancing Barrier via Adsorption of Microplastics to Reduce Intestinal Translocation
-Enhancing Tight Junction and Reducing Microplastic-Induced Intestinal Epithelial Damage
-Enhancing Intestinal Motility, Maintaining Gut Microbiota Diversity
Get In Touch